Incretin Atlas › Trials › VENTURE (phase 2, s.c.)
VENTURE (phase 2, s.c.)
VK2735 · obesity
Design
- Molecule(s)
- VK2735
- Population
- obesity
- Phase
- 2
- Participants
- 36
- Duration
- 13 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VK2735 5.0 mg weekly | obesity | 13 | 35 | −10.9 % vs −1.7 % Δ −9.2 pp | — | −0.3 vs +0.0 | 11.0 vs 0.0 | 11.0 vs 14.0 | 46.0 vs 20.0 | 17.0 vs 0.0 | 6.0 vs 3.0 | −6.7 vs −4.2 | verified |
| VK2735 10 mg weekly | obesity | 13 | 36 | −12.9 % vs −1.7 % Δ −11.2 pp | — | −0.3 vs +0.0 | 11.0 vs 0.0 | 14.0 vs 14.0 | 37.0 vs 20.0 | 17.0 vs 0.0 | 6.0 vs 3.0 | −7.0 vs −4.2 | verified |
| VK2735 15 mg weekly | obesity | 13 | 35 | −14.7 % vs −1.7 % Δ −13.0 pp | — | −0.4 vs +0.0 | 20.0 vs 0.0 | 20.0 vs 14.0 | 63.0 vs 20.0 | 29.0 vs 0.0 | 3.0 vs 3.0 | −11.0 vs −4.2 | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (24)
- VK2735 5.0 mg weekly · weight_eff · Table 2
LS Mean (95% CI) −1.7 (−3.03, −0.30) −9.1 (−10.43, −7.76) −10.9 (−12.25, −9.55) −12.9 (−14.30, −11.56) −14.7 (−16.11, −13.38)
- VK2735 5.0 mg weekly · ae_dc · Table 3
TEAE leading to treatment discontinuation 0 1 (3) 4 (11) 4 (11) 7 (20)
- VK2735 5.0 mg weekly · disc_any · Table 3
Discontinued treatment early, n (%)c 5 (14) 2 (6) 4 (11) 5 (14) 7 (20)
- VK2735 5.0 mg weekly · nausea · Table 3
Nausea 7 (20) 9 (26) 16 (46) 13 (37) 22 (63)
- VK2735 5.0 mg weekly · vomiting · Table 3
Vomiting 0 3 (9) 6 (17) 6 (17) 10 (29)
- VK2735 5.0 mg weekly · sae · Table 3
TESAEs, n (%)a 1 (3) 2 (6) 2 (6) 2 (6) 1 (3)
- VK2735 5.0 mg weekly · hba1c · Table 5, Hemoglobin A1c
Change from BL, LS Mean (SE) 0.03 (0.041) −0.29 (0.040) −0.27 (0.040) −0.27 (0.039) −0.36 (0.040)
- VK2735 5.0 mg weekly · sbp · Table 5, Systolic blood pressure
Change from BL, LS Mean (SE) −4.20 (1.993) −6.87 (1.906) −6.71 (1.931) −7.04 (1.936) −10.97 (2.000)
- VK2735 10 mg weekly · weight_eff · Table 2
LS Mean (95% CI) −1.7 (−3.03, −0.30) −9.1 (−10.43, −7.76) −10.9 (−12.25, −9.55) −12.9 (−14.30, −11.56) −14.7 (−16.11, −13.38)
- VK2735 10 mg weekly · ae_dc · Table 3
TEAE leading to treatment discontinuation 0 1 (3) 4 (11) 4 (11) 7 (20)
- VK2735 10 mg weekly · disc_any · Table 3
Discontinued treatment early, n (%)c 5 (14) 2 (6) 4 (11) 5 (14) 7 (20)
- VK2735 10 mg weekly · nausea · Table 3
Nausea 7 (20) 9 (26) 16 (46) 13 (37) 22 (63)
- VK2735 10 mg weekly · vomiting · Table 3
Vomiting 0 3 (9) 6 (17) 6 (17) 10 (29)
- VK2735 10 mg weekly · sae · Table 3
TESAEs, n (%)a 1 (3) 2 (6) 2 (6) 2 (6) 1 (3)
- VK2735 10 mg weekly · hba1c · Table 5, Hemoglobin A1c
Change from BL, LS Mean (SE) 0.03 (0.041) −0.29 (0.040) −0.27 (0.040) −0.27 (0.039) −0.36 (0.040)
- VK2735 10 mg weekly · sbp · Table 5, Systolic blood pressure
Change from BL, LS Mean (SE) −4.20 (1.993) −6.87 (1.906) −6.71 (1.931) −7.04 (1.936) −10.97 (2.000)
- VK2735 15 mg weekly · weight_eff · Table 2
LS Mean (95% CI) −1.7 (−3.03, −0.30) −9.1 (−10.43, −7.76) −10.9 (−12.25, −9.55) −12.9 (−14.30, −11.56) −14.7 (−16.11, −13.38)
- VK2735 15 mg weekly · ae_dc · Table 3
TEAE leading to treatment discontinuation 0 1 (3) 4 (11) 4 (11) 7 (20)
- VK2735 15 mg weekly · disc_any · Table 3
Discontinued treatment early, n (%)c 5 (14) 2 (6) 4 (11) 5 (14) 7 (20)
- VK2735 15 mg weekly · nausea · Table 3
Nausea 7 (20) 9 (26) 16 (46) 13 (37) 22 (63)
- VK2735 15 mg weekly · vomiting · Table 3
Vomiting 0 3 (9) 6 (17) 6 (17) 10 (29)
- VK2735 15 mg weekly · sae · Table 3
TESAEs, n (%)a 1 (3) 2 (6) 2 (6) 2 (6) 1 (3)
- VK2735 15 mg weekly · hba1c · Table 5, Hemoglobin A1c
Change from BL, LS Mean (SE) 0.03 (0.041) −0.29 (0.040) −0.27 (0.040) −0.27 (0.039) −0.36 (0.040)
- VK2735 15 mg weekly · sbp · Table 5, Systolic blood pressure
Change from BL, LS Mean (SE) −4.20 (1.993) −6.87 (1.906) −6.71 (1.931) −7.04 (1.936) −10.97 (2.000)
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: VENTURE (phase 2, s.c.). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/venture/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.